Great improvements have been made in the last years in the treatment of different chronic inflammatory diseases such as Inflammatory Bowel Disease (IBD) or Rheumatoid Arthritis (RA). Antibody based drugs, so called biologics, which target TNF-alpha had a marked impact on the treatment success and quality of life of patients. Among TNF-alpha inhibitors, infliximab and adalimumab are the most commonly used biologics.
These drugs come with side-effects, are expensive and are not always effective in all patients. To maximize treatment success, it is important that the therapy of patients is being followed closely. It is important that patients have optimal drug levels, since low drug concentrations in patient serum may have worse treatment outcomes. Therapeutic drug monitoring (TDM) of trough levels and antibodies against anti-TNF drugs allows to identify patients having suboptimal drug levels or developing antibodies against anti-TNF drugs.
BÜHLMANN Laboratories is proud to announce the addition of the CE marked Quantum Blue® Anti-Adalimumab to our TDM rapid test portfolio. With this new lateral flow test we provide a highly specific qualitative detection of antibodies against adalimumab within 15 minutes.